Cvs Cold and Hot

Description

This formulation contains menthol at a concentration of 10% and methyl salicylate at 30%. It is presented as a pain-relieving stick, designed for topical application. The net weight of the product is 2 ounces (56.7 grams). The National Drug Code (NDC) for this product is 10889-202-11.

Uses and Indications

This drug is indicated for the temporary relief of minor aches and pains associated with various conditions, including arthritis, simple backache, bursitis, tendonitis, muscle strains, muscle sprains, bruises, and cramps.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

For adults and children aged 10 years and older, the recommended dosage is to apply the product generously to the affected area. The area should be massaged until the product is thoroughly absorbed into the skin. This application may be repeated as necessary, but should not exceed four times daily.

For children under 10 years of age, it is advised to consult a healthcare professional before use.

Contraindications

Use of this product is contraindicated in the following situations:

• Tight bandaging or application with a heating pad is not recommended, as this may lead to adverse effects.

• Contact with eyes and mucous membranes should be avoided to prevent irritation or injury.

• Application to wounds or damaged skin is contraindicated due to the risk of exacerbating the condition or causing further harm.

Warnings and Precautions

For external use only. Healthcare professionals should advise patients to consult a physician if they are pregnant or breastfeeding prior to use.

An allergy alert is warranted; patients should not use this product if they have a known allergy to salicylates, including aspirin, without prior consultation with a healthcare provider.

In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center should be contacted without delay.

Patients are advised to discontinue use and consult a physician if any of the following occur: the condition worsens, symptoms persist for more than 7 days, symptoms resolve and then recur within a few days, redness appears, or irritation develops. Monitoring for these signs is essential to ensure patient safety and effective management of their condition.

Side Effects

Patients should be aware of the potential for serious adverse reactions associated with the use of this medication. An allergy alert is in place, advising against use in individuals with known allergies to salicylates, including aspirin, without prior consultation with a physician.

In clinical practice, patients are advised to stop using the medication and seek medical advice if any of the following occur: if the condition worsens, if symptoms persist for more than 7 days, or if symptoms resolve only to recur within a few days. Additionally, the presence of redness or the development of irritation should prompt immediate consultation with a healthcare provider.

These precautions are essential to ensure patient safety and to mitigate the risk of adverse effects during treatment.

Drug Interactions

Patients with a known allergy to salicylates, including aspirin, should avoid the use of this medication unless they have consulted with a physician. This precaution is essential to prevent potential allergic reactions.

No specific drug or laboratory test interactions have been identified in the available data. Therefore, routine monitoring or dosage adjustments related to drug interactions are not necessary. However, healthcare providers should remain vigilant and consider individual patient circumstances when prescribing this medication.

Packaging & NDC

Below are the non-prescription pack sizes of Cvs Cold and Hot (methyl salicylate and menthol). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 10 years of age should consult a healthcare professional before use. It is important to assess the appropriateness of treatment and dosage for this age group, as specific recommendations may vary based on individual health needs and conditions.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully weighed, as the effects on fetal outcomes and lactation are not fully established. It is essential for women of childbearing potential to seek medical advice to ensure the safety of both the mother and the developing fetus.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is no specific data available regarding the excretion of this medication in breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating mothers.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution when administering the medication. It is essential to monitor patients closely for any signs of adverse effects or symptoms that may arise from excessive dosing.

In the event of suspected overdosage, immediate medical attention should be sought. Healthcare providers should implement supportive measures as necessary, which may include symptomatic treatment and monitoring of vital signs.

Due to the lack of detailed overdosage information, it is recommended that healthcare professionals refer to established clinical guidelines and protocols for managing overdose situations relevant to the specific medication in question. Additionally, contacting a poison control center may provide valuable assistance in the management of overdosage cases.

Continued vigilance and adherence to recommended dosing guidelines are crucial to minimize the risk of overdosage and ensure patient safety.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the product is swallowed. It is important to instruct patients to discontinue use and consult a doctor if their condition worsens or if symptoms persist for more than 7 days. Patients should also be informed to stop using the product and seek medical advice if they notice any redness or if irritation develops.

When discussing the use of this product, healthcare providers should emphasize the importance of using it only as directed. Patients should be cautioned against bandaging tightly or using the product in conjunction with a heating pad. Additionally, it is crucial to advise patients to avoid contact with their eyes and mucous membranes, and to refrain from applying the product to wounds or damaged skin.

Storage and Handling

The product is supplied in configurations that include specific NDC numbers. It should be stored at room temperature, ensuring that it is protected from excessive heat. Additionally, it is important to keep the product out of reach of children. Once opened, the product must be discarded to ensure safety and efficacy.

Additional Clinical Information

The product is administered topically, with patients advised to apply it generously to the affected area and massage until thoroughly absorbed into the skin. Applications may be repeated as necessary, but should not exceed four times daily.

Clinicians should counsel patients to consult a health professional if they are pregnant or breastfeeding. An allergy alert is in place for individuals allergic to salicylates, including aspirin, who should seek medical advice before use. Patients are instructed to use the product only as directed, avoiding tight bandaging or the use of heating pads, and to prevent contact with eyes and mucous membranes. It should not be applied to wounds or damaged skin. Patients should discontinue use and consult a doctor if their condition worsens, symptoms persist beyond seven days, or if redness or irritation develops. Additionally, the product should be kept out of reach of children, and immediate medical assistance should be sought if ingested.

Drug Information (PDF)

This file contains official product information for Cvs Cold and Hot, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)